BristolMyers Squibb Company  (BMY) Trade Now »     Rate BMY  -  Discuss BMY  -  Add to Watch List        

Filed under: Apple Inc (AAPL), Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy

Filed under: Intel (INTC), Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy

"Many growth and income investors will eventually need to start taking dividends to supplement other forms of cash ???ow," says Chuck Carlson, an expert in dividend reinvestment plans.

The editor of the DRIP Investor explains, "And many investors would like to receive those dividends on a regular basis. And, in fact, you can get monthly dividend check from a portfolio holding just three stocks.

Continue reading Monthly Dividends from a 3-Stock Growth Portfolio

Filed under: Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy

"Foreign corporations have been on a mini buying spree in 2010. Not surprising, merger and acquisition activity has heated up a bit in the drug sector," says Chuck Carlson, editor of The DRIP Investor.

The dividend expert explains, " Global merger and acquisition activity topped $1 trillion in the ???rst half of 2010, a 9.4% increase over the previous year. And Bristol-Myers Squibb (BMY), recommend stock in our Editor's Portfolio, has been one of the more active participants.

Filed under: Stocks to Buy

Continue reading Protective Parents Could Send Mead Johnson Higher

<font> On 7/9/10, Bristol-Myers (NYSE:BMY) announced that the FDA accepted its supplemental New Drug Application (sNDA) for a priority (six-month) review to expand the product label for SPRYCEL (dasatinib) (an oral BCR-ABL inhibitor anti-cancer agent) to include the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase. </font>

Filed under: Stocks to Buy

Continue reading Skin Cancer Breakthrough Boosts Bristol-Myers

Filed under: Bristol-Myers Squibb (BMY), Stocks to Buy

"Although the new health care legislation means that the pharmaceutical industry will face about $90 billion in new taxes and fees over time, the legislation also brings many benefits to pharmaceutical companies including a potentially huge influx of new customers now able to afford prescription medication through insurance coverage," says Melvin Pasternak.

Filed under: Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy

"It's time for income investors to come back to what's historically been a mainstay of diversified portfolios: big pharmaceutical companies. We're adding one of the sector's most durable members to the Income Portfolio, Bristol-Myers Squibb (BMY)," says Roger Conrad.

In Personal Finance newsletter, he explains, "The stock has been a lackluster performer since the 1990s, when it was last a Portfolio recommendation. The company's underlying business, however, has become ever-more valuable.

Filed under: Newsletters, Abbott Laboratories (ABT), Baxter Intl (BAX), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Stocks to Buy

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

Filed under: Apple Inc (AAPL), Ford Motor (F), Exxon Mobil (XOM), China, Market matters, Citigroup Inc. (C), Target Corp. (TGT), BB and T (BBT), Bristol-Myers Squibb (BMY), Wendy's Intl (WEN), BHP Billiton Ltd ADR (BHP), Freep't McMoRan Copper (FCX), Stocks to Buy, Union Pacific Corporation (UNP), Cramer on BloggingStocks, Potash Corp. of Saskatchewan (POT)

From TheStreet.com Network

• Here We Go Again? Asian Markets Plunge
• Is the Pullback Over?: Dow Watch

Filed under: Pfizer (PFE), Market matters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Stocks to Buy, Cramer on BloggingStocks

From TheStreet.com Network

• Coming Week: More Earnings, Upside
• Higher Medical Costs Crimp Aetna Profits

Filed under: Earnings reports, Newsletters, Bristol-Myers Squibb (BMY), Stocks to Buy

"Wall Street has been nonplussed about results from Bristol-Myers Squibb (NYSE: BMY); in my view, the Street is wrong," says Karim Rahemtulla in Xcelerated Profits Report.

"The stock has not joined many of its colleagues on the upside recently, but you can take Wall Street's lackluster opinion with a grain of salt. Yes, BMY's revenue of $5.02 billion fell a bit shy of projections for $5.13 billion, mostly due to a strong dollar negatively impacting sales.